PLGA-Coated RTX Nanoparticles for Transdermal Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical treatments for diabetic peripheral neuropathy (DPN) often cause pain during application and have significant adverse effects, such as erythema and pruritis, due to high concentrations of capsaicin or other TRPV1 agonists, and there is a need for efficient delivery of resiniferatoxin (RTX) through the transdermal barrier to effectively alleviate pain without these side effects.
Innovation Solution
Development of topical formulations containing PLGA-coated resiniferatoxin nanoparticles, which provide a gradual and consistent release of RTX in extremely low, yet therapeutically effective doses, ranging from 100 femtomolar to one micromolar, to treat DPN and other pain-related conditions without causing pain at the application site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of capsaicin or TRPV1 agonists are used in topical treatments, then pain relief effectiveness is improved, but adverse effects such as erythema, pruritis, and pain during application increase
Solution Approach 1:
The patent changes the concentration parameter of TRPV1 agonists from high (conventional) to extremely low (100 femtomolar to one micromolar), achieving effective pain relief while eliminating adverse effects. This parameter change is enabled by the nanoparticle delivery system which enhances drug penetration and utilization efficiency.
Solution Approach 2:
PLGA-coated nanoparticles serve as an intermediary carrier that delivers TRPV1 agonists through the transdermal barrier. The nanoparticle structure (1-200 nm size with specific PLGA composition) mediates between the drug and skin tissue, enabling controlled release and reducing direct irritation while maintaining therapeutic effectiveness.
2Reliability
If resiniferatoxin is delivered through the transdermal barrier, then pain management effectiveness is improved, but delivery efficiency through skin barrier is initially insufficient
Solution Approach 1:
The patent transitions from conventional topical application (surface level) to nanoparticle-mediated transdermal delivery (penetrating through layers). By reducing drug size to nanoparticle dimension (1-200 nm) and utilizing the PLGA coating's specific properties, the system achieves effective penetration through the stratum corneum and into deeper tissue layers where nociceptors are located.
Solution Approach 2:
The patent changes physical parameters including particle size (1-200 nm), polymer composition (PLGA with specific lactic/glycolic acid ratios), and drug concentration (extremely low femtomolar to micromolar ranges). These parameter changes optimize transdermal penetration efficiency while controlling release kinetics for sustained pain relief.
3Object-affected harmful factors
If extremely low doses of resiniferatoxin are used, then adverse effects are reduced, but therapeutic effectiveness may be insufficient
Solution Approach 1:
The PLGA-coated nanoparticle acts as an intermediary that protects the TRPV1 agonist from degradation and controls its release. The nanoparticle carrier enhances the drug's stability, penetration capability, and target-specific delivery, allowing extremely low doses to achieve therapeutic effectiveness that would otherwise require much higher concentrations.
Solution Approach 2:
The patent utilizes extreme parameter reduction in drug concentration (100 femtomolar to one micromolar) while compensating through optimized nanoparticle parameters (size, composition, coating). This parameter optimization enables ultra-low dosing with maintained efficacy by improving drug utilization efficiency at the target site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PLGA-coated RTX nanoparticles efficiently deliver RTX through the transdermal barrier, providing effective pain management and inflammation treatment with minimal side effects, inducing a depolarization block of nerve terminals for short-term pain relief and long-term desensitization, thus addressing the limitations of existing treatments.
Implementation Method 1
The PLGA-coated RTX nanoparticles efficiently deliver RTX through the transdermal barrier
Implementation Method 2
efficiently deliver RTX through the transdermal barrier
Implementation Method 3
provide a gradual and consistent release of RTX
Implementation Method 4
provide a gradual and consistent release of RTX
Implementation Method 5
inducing a depolarization block of nerve terminals for short-term pain relief
Implementation Method 6
long-term desensitization
Data Source
AI summary
Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.